Navigation Links
Amicus Therapeutics Presents Data from Clinical Ex Vivo Response Study and Phase 1 Studies of AT2220
Date:3/13/2008

Data Suggest Majority of Pompe Patients May Be Amenable to Chaperone

Therapy

CRANBURY, N.J., March 13 /PRNewswire/ -- Amicus Therapeutics, a biopharmaceutical company developing small-molecule, orally administered pharmacological chaperones for the treatment of human genetic diseases, announced today that the Company will present positive results from an ex vivo response study and three Phase 1 studies of AT2220 (1-deoxynojirimycin HCl), Amicus' compound in development for the treatment of Pompe disease, at the American College of Medical Genetics (ACMG) Annual Meeting from March 12-16 in Phoenix, AZ. The results of the ex vivo response study along with the previously reported results of the Phase 1 studies support moving into Phase 2 trials in the first half of 2008.

Ex Vivo Response Study data

Interim data will be presented from an ex vivo response study designed to test the effect of AT2220 on various Pompe mutations. Blood and skin samples were collected from 30 Pompe patients (26 adults, 3 juveniles and 1 infant) with a variety of different mutations in acid alpha-glucosidase (GAA), the target enzyme in Pompe disease. Cells derived from these samples were then tested to determine whether treatment with AT2220 caused an increase in the level of GAA. Of the 26 patients with available data, 24 had cells that showed a dose responsive increase in GAA levels, including 22 patients who had at least 1 copy of the common splice site mutation IVS1-13T>G. It has been reported that more than 80% of Caucasian adult Pompe patients have at least 1 copy of this common splicing mutation.

Phase 1 AT2220 data

A total of 72 healthy volunteers were treated in three double-blind, placebo-controlled, dose escalation Phase 1 studies designed to evaluate the safety, tolerability and pharmacokinetics of AT2220. Across all three studies, AT2220 was shown to be generally safe and well tolerated at all doses. The
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Amicus Therapeutics to Present at the 26th Annual JPMorgan Healthcare Conference
2. Amicus Therapeutics Announces Positive Results From Two Phase 1 Clinical Studies of AT2220 for Pompe Disease
3. Amicus Therapeutics Announces Plans to Present Phase 1 Data for AT2220 for Pompe Disease
4. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
5. Ception Therapeutics Initiates Phase II/III Clinical Trial for Its Lead Product Reslizumab in Eosinophilic Esophagitis (EE) in Children
6. Cell Therapeutics, Inc. (CTI) Submits European Marketing Authorization Application for XYOTAX(TM)
7. InteKrin Therapeutics Announces Initiation of Phase 2b Study in Type 2 Diabetes with INT131
8. Oncology Drug Development Update - Molecular Profiling Redefines the Nature of Malignancy and Increases the Adoption of Targeted Therapeutics
9. TorreyPines Therapeutics Announces Strategic Plan with Focus on Clinical Development Activities to Maximize Value of Versatile Lead Compounds
10. Horizon Therapeutics Completes Enrollment in Phase 3 Trials for Lead Product Candidate HZT-501
11. Multiple Dose Clinical Trial of TorreyPines Therapeutics Tezampanel Demonstrates Compound is Safe and Well-Tolerated
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... Reportlinker.com announces that a new market research report ... Patient Scales Industry http://www.reportlinker.com/p01374301/Global-Patient-Scales-Industry.html ... markets for Patient Scales in US$ Thousand by ... Baby Scales, Chair Scales, and Under Bed Scales. ... US, Canada, Japan, Europe, Asia-Pacific, Latin America, and ...
(Date:8/20/2014)... MUMBAI , August 20, 2014 ... owned subsidiary of Glenmark Pharmaceuticals Limited India (GPL), ... studies of a novel clinical development candidate, GBR ... discovered and developed by the Glenmark Biologics Research ... . GBR 1302 is based on Glenmark,s ...
(Date:8/19/2014)... , Aug. 19, 2014  The Alabama Supreme Court, in ... can sue drug makers who mislead doctors into believing that ... The case is Weeks v. Wyeth, and the decision came ... that same case last year. Heninger Garrison Davis attorneys ... patient in the case, Danny Weeks . ...
Breaking Medicine Technology:Global Patient Scales Industry 2Global Patient Scales Industry 3Global Patient Scales Industry 4Global Patient Scales Industry 5Global Patient Scales Industry 6Global Patient Scales Industry 7Global Patient Scales Industry 8Global Patient Scales Industry 9Global Patient Scales Industry 10Global Patient Scales Industry 11Global Patient Scales Industry 12Global Patient Scales Industry 13Global Patient Scales Industry 14Global Patient Scales Industry 15Global Patient Scales Industry 16Global Patient Scales Industry 17Global Patient Scales Industry 18Global Patient Scales Industry 19Glenmark Enters Oncology With the Discovery and Initiation of IND Enabling Studies of an Innovative Bispecific Antibody 2Glenmark Enters Oncology With the Discovery and Initiation of IND Enabling Studies of an Innovative Bispecific Antibody 3Heninger Garrison Davis Clients To Get Their Day in Court Against Brand Drug Companies 2Heninger Garrison Davis Clients To Get Their Day in Court Against Brand Drug Companies 3Heninger Garrison Davis Clients To Get Their Day in Court Against Brand Drug Companies 4
... 6, 2011 Actavis, an international generic pharmaceuticals ... approval from the US Food & Drug Administration ... mg CIV.  Distribution of the product has commenced. ... to launch Zolpidem Tartrate Extended-Release Tablets 6.25 mg strength ...
... June 6, 2011 Brainlab announced today ... acquire Voyant Health. Voyant Health,s core technology, ... and to plan and digitally template surgical procedures from ... the operating room (OR). Another key technology is VoyantLink™, ...
Cached Medicine Technology:Actavis Receives FDA Approval of Zolpidem Tartrate Extended-Release Tablets USP, 12.5 mg CIV in the U.S. 2Brainlab Acquires Voyant Health 2Brainlab Acquires Voyant Health 3
(Date:8/20/2014)... have discovered that the immune system is defective in people ... why sufferers have ongoing issues with pain. , The research ... could also help to explain why some painkillers may not ... affects up to 10% of the community. There are ... gut pain, which often has the greatest impact on sufferers, ...
(Date:8/20/2014)... Hundreds of Mirena IUD lawsuits ( http://www.themirenalawsuitcenter.com/ ... allegedly injured due to spontaneous migration of the IUD ... Superior Court, Bernstein Liebhard LLP reports. According to a ... Court has established procedures regarding the production of sales ... of the proceeding’s initial disposition pool. (In Re: Mirena ...
(Date:8/20/2014)... News) -- Loss of brain cells that act as ... have trouble falling and staying asleep, a new study ... especially severe and often results in nighttime confusion and ... data from the Rush Memory and Aging Project, which ... and are being followed until death, at which point ...
(Date:8/20/2014)... HealthDay Reporter WEDNESDAY, Aug. 20, 2014 ... been an option, but a new study shows that only ... common reasons women didn,t undergo reconstruction was that they felt ... they were focused on their cancer treatment," said lead researcher ... Kettering Cancer Center, in New York City. Also common ...
(Date:8/20/2014)... and deadliest infectious diseases in the world, killing one ... study tuberculosis have long debated its origins. New research ... to seals and sea lions that brought the disease ... there before Europeans landed on the continent. , The ... of New World Human Tuberculosis," was published in ...
Breaking Medicine News(10 mins):Health News:Pain treatments less effective for those with irritable bowel 2Health News:Mirena Lawsuit News: Case Management Order Issued in New Jersey Mirena Litigation, Bernstein Liebhard LLP Reports 2Health News:Mirena Lawsuit News: Case Management Order Issued in New Jersey Mirena Litigation, Bernstein Liebhard LLP Reports 3Health News:Mirena Lawsuit News: Case Management Order Issued in New Jersey Mirena Litigation, Bernstein Liebhard LLP Reports 4Health News:Seniors' Sleep Woes May Be Linked to Loss of Brain Cells 2Health News:Many Women Who Have Mastectomy Don't Get Breast Reconstruction: Study 2Health News:Many Women Who Have Mastectomy Don't Get Breast Reconstruction: Study 3Health News:New research shows seals and sea lions likely spread tuberculosis to humans 2Health News:New research shows seals and sea lions likely spread tuberculosis to humans 3
... (UPH) in Tucson, Arizona has selected Broadlane to provide an ... Financial terms were not announced. , ... ... announced today that University Physicians Healthcare (UPH) in Tucson, Arizona ...
... MONTREAL, Sept. 11 /PRNewswire-FirstCall/ - Haemacure ... company developing,high-value human plasma-derived protein products for ... second preclinical study,conducted on the use of ... sealant Hemaseel(R)HMN, in preventing the formation of ...
... Eye Institute have opened a new office to better serve their clients. ... ... Pennsylvania is proud to announce the opening of their new office in ... and the new location is currently receiving patients for eye care and ...
... to Combat Diabetes in Local,Community, NEW YORK, Sept. ... Month and to recognize those in the,Hispanic/Latino population who ... Association is hosting Feria de Salud, Por Tu Familia ... South Bronx from 11:00,a.m. - 4:00 p.m. Actor Tony ...
... Injured, workers and passersby developed psychological, respiratory woes, latest ... -- Two to three years after the 9/11 terrorist ... elevated among people enrolled in the World Trade Center ... health department study. , Released on the eve of ...
... 10 Lincoln Park Performing Arts,Center ( http://www.lppac.org/ ... on Sept. 12-14, 2008. Leading neurologist and,mind-body researcher ... present the program at the Lincoln Park facility ... various group drumming exercises,that can benefit their health. ...
Cached Medicine News:Health News:University Physicians Healthcare (UPH) Selects Broadlane to Provide Comprehensive Supply Chain Services 2Health News:University Physicians Healthcare (UPH) Selects Broadlane to Provide Comprehensive Supply Chain Services 3Health News:University Physicians Healthcare (UPH) Selects Broadlane to Provide Comprehensive Supply Chain Services 4Health News:Adhesion Prevention New Major Market Opportunity, Haemacure Confirms Effectiveness of its Fibrin Sealant in Second Preclinical Study in Adhesion Prevention in a Bleeding Model 2Health News:Adhesion Prevention New Major Market Opportunity, Haemacure Confirms Effectiveness of its Fibrin Sealant in Second Preclinical Study in Adhesion Prevention in a Bleeding Model 3Health News:Northeastern Eye Institute Opens New Office 2Health News:American Diabetes Association Kicks 0ff Hispanic Heritage Month 2Health News:9/11's Health Effects Lingered for Years 2Health News:9/11's Health Effects Lingered for Years 3Health News:Lincoln Park Performing Arts Center to Host Highly Acclaimed Music and Medicine Program 2
Sterile Disposable Thermal Cautery Tips for Vasectomy. Individually peel-pouched with dual plastic sheaths to cover non-sterile handle. Box of 10 tips....
... ideal for applications such as vasectomy ... , ,The autoclavable handpiece with six-foot ... thermal cautery electrodes, allowing the physician ... a wide variety of procedures., ,The ...
Non-Cantilevered Ringed Forceps. ("fixation clamp") For vasectomy and other procedures. Ring diameter approximately 3.0 mm....
... for users of "completely-in-the-canal" (CIC) instruments ... - must send eartip., ,Impressions ... ,Westone custom products for the ... network of hearing healthcare providers. These ...
Medicine Products: